Plasma proteomics has long held great potential for both biomarker discovery and clinical development, providing a minimally invasive means to measure tissue biology, identify early biomarkers of disease, and monitor disease progression and therapeutic response over time. However, the complexity of the human plasma proteome has precluded broad measure via plasma proteomics and limited its utility for drug development, until now.
This webinar will explore the recent technological developments finally allowing drug developers to extract maximal biological insight from the plasma proteome, with deeper coverage and with greater efficiency for large-scale studies. We will look at methodologies that are overcoming previous trade-offs in measurement speed, sensitivity, and specificity; enrichment techniques enabling detection of biologically/clinically relevant low-abundance proteins in plasma; and why approaches that capture protein isoforms as well as exosomal and membrane-bound proteins have become so critical in 2025.
Importantly, we will review the types of robust analyses that can now be enabled in plasma and share examples of how this data is contributing to the advancement of target identification and precision medicine.
Please fill in the form below to access this content:
Speaker Biographies
Mo Jain, MD, PhD
Founder and Chief Scientific Officer, Sapient
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, computational biology, and mass spectrometry. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe dynamic biomarkers of health, disease, and drug response across population-scale human studies. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating insight into human biology to advance precision drug development.
Jeramie Watrous, PhD
Co-Founder and Head of Analytical R&D, Sapient
Dr. Watrous is an analytical chemist and engineer with more than a decade of experience using mass spectrometry for biological measures and associated informatics. As a postdoctoral researcher and subsequently an Assistant Professor of Medicine at UCSD, he helped lead the development of fully automated, high throughput mass spectrometry-based workflows for global small molecule biomarker analysis – the next-generation technology that became the basis for Sapient, which he co-founded in 2021. At Sapient, Dr. Watrous oversees the generation, optimization, and standardization of Sapient’s mass spectrometry systems and other innovative instrumentation and lab automation infrastructure.
